Health Trials

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

ConditionsB-Cell Non-Hodgkin's Lymphoma (NHL)Lymphoma, Non-HodgkinsLymphomas Non-Hodgkin's B-CellNon-Hodgkin LymphomaNon-Hodgkin's LymphomaLarge B-Cell LymphomaLymphoma, Non-Hodgkin's, AdultLymphomaRefractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin LymphomaLymphoma, Non-HodgkinHIV Associated LymphomaCNS LymphomaHigh-grade B-cell LymphomaRefractory B-Cell Non-Hodgkin Lymphoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorEstrella Biopharma, Inc.

About this trial

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase.

Eligibility criteria

Qualifiers

Age 18 years or older at the time of informed consent

Histologically confirmed R/R B-cell non-Hodgkin's lymphoma (NHL)

Adequate organ function

R/R after ≥ 2 lines of systemic therapy

Disqualifiers

Prior CD19-targeted cellular therapy

History of Richter's transformation of chronic lymphocytic leukemia (CLL)

History of another primary malignancy that has not been in remission for ≥ 2 years.

History or presence of clinically relevant Central Nervous System (CNS) pathology

Trial design

Treatments tested in this trial

  • EB103

Treatment groups

21 Participants
are divided into 1 treatment group

Locations

2
University of California, Davis95817, SacramentoCalifornia, United States
Baylor Scott & White Research Institute, Texas Oncology75246, DallasTexas, United States

Sponsors and collaborators

Estrella Biopharma, Inc.

Lead sponsor

Eureka Therapeutics Inc.

Collaborator

Source ClinicalTrials.gov